Treatment with type-2 selective and non-selective cyclooxygenase inhibitors improves T-cell proliferation in HIV-infected patients on highly active antiretroviral therapy

AIDS. 2004 Apr 9;18(6):951-2. doi: 10.1097/00002030-200404090-00015.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antiretroviral Therapy, Highly Active
  • Cell Division
  • Cyclooxygenase Inhibitors / therapeutic use*
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • Humans
  • Indomethacin / therapeutic use*
  • Lactones / therapeutic use*
  • Lymphocyte Count
  • Male
  • Middle Aged
  • Sulfones
  • T-Lymphocytes / immunology*
  • Viral Load

Substances

  • Cyclooxygenase Inhibitors
  • Lactones
  • Sulfones
  • rofecoxib
  • Indomethacin